RxDoctor Payments Data

Robert Noh, MD

Urology · South Plainfield, NJNPI 1962417303

Payments from drug & device makers

$5,301in general payments, 2019–2025

Across 309 payments — averaging $17.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$1K
  • Antares Pharma, Inc.$518
  • AbbVie$513
  • Sumitomo Pharma America, Inc.$503
  • Pfizer$339
  • Johnson & Johnson$230
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$4,73989%
  • Education$56111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,301 in reported general payments places this provider in the 70th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$561,279
Medicare patients
1,319
Services billed
26,623

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide33$618,825
MyrbetriqMirabegron13$13,519
GemtesaVibegron18$11,732
Tamsulosin Hcl161$2,995
Methenamine Hippurate39$2,602
Alfuzosin Hcl ErAlfuzosin Hcl35$1,247
Finasteride96$1,192
Estradiol15$900
Levofloxacin137$429
Tolterodine Tartrate ErTolterodine Tartrate12$409
Solifenacin Succinate12$343
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst32$319
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip18$182
Phenazopyridine Hcl15$151
CefuroximeCefuroxime Axetil13$137

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,434$632,34446 claims
Sumitomo Pharma America, Inc.Gemtesa$503$11,73218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 401 urology providers in New Jersey.

Other urology in South Plainfield

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →